Johnson & Johnson (JNJ) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Johnson & Johnson has just announced its 64th consecutive year of dividend increases, reinforcing its image as a bullet‑proof dividend stock. The dividend hike comes amid ongoing talcum powder litigation that could erode earnings in the near term. Historically, JNJ has weathered regulatory and market shocks—most notably the 1980s Tylenol crisis—demonstrating its ability to maintain shareholder returns even under pressure. The continued dividend growth signals that management believes cash flow remains robust enough to sustain payouts despite legal headwinds. For the next 1–10 trading days, investors should interpret the dividend announcement as a bullish sign of financial health, while remaining cautious of any sudden litigation settlements that could hit earnings. The company’s earnings guidance will be a key watch item, as any downward revision could trigger a reassessment of the dividend’s sustainability. Additionally, monitoring the progress of the talcum powder lawsuits—particularly any large settlements or regulatory rulings—will help gauge potential cash outflows. Analysts will also keep an eye on JNJ’s cash reserves and debt levels, which underpin its capacity to continue dividend growth. Finally, any change in the company’s dividend policy or payout ratio will be a critical signal for investors looking to adjust their exposure in the coming days.

JNJ|Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NYQ

Country

United States

Website

jnj.com

Symbol

JNJ

Description

Johnson & Johnson is a global healthcare giant focused on two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division develops and markets prescription drugs targeting a broad range of therapeutic areas, including immunology, oncology, neuroscience, and cardiovascular diseases, reaching patients through various distribution channels. The MedTech segment provides a diverse portfolio of medical devices and technologies, such as those used in electrophysiology, orthopedics, surgery, and vision care, including contact lenses and intraocular lenses. This segment serves hospitals, retailers, and healthcare professionals. Founded in 1886, Johnson & Johnson leverages its extensive research and development capabilities to deliver innovative healthcare solutions worldwide, solidifying its position as a diversified leader in the industry.

JNJ|Earnings Snapshot

Earnings Summary

Johnson & Johnson, a global healthcare conglomerate, operates through its Innovative Medicine and MedTech segments, delivering prescription drugs across immunology, oncology, neuroscience, and cardiovascular fields while supplying a broad array of medical devices to hospitals and retailers; the company’s diversified portfolio anchors it within the drug manufacturers sector. In the most recent two quarters, J&J reported Q4 2025 revenue of $24.56 billion, narrowly beating the $24.40 billion estimate, and an EPS of $2.46 versus the $2.46 estimate, while Q1 2026 revenue fell to $24.06 billion against a $25.03 billion forecast and EPS of $2.70 versus the $2.88 estimate, indicating a shift from the prior two quarters’ double‑beat performance where Q2 2025 and Q3 2025 EPS surpassed estimates of $2.68 and $2.76 respectively and revenue grew steadily; the trend shows a recent deceleration in both earnings and top line growth. Over the past few years, J&J has maintained a consistent YoY revenue expansion, with Q4 2025 revenue up 9.3 % from Q4 2024 and Q1 2026 revenue up 10.5 % from Q1 2025, while EPS growth peaked in Q4 2025 at 20.6 % YoY before a slight decline in Q1 2026, underscoring a pattern of strong earnings beats punctuated by occasional misses that do not erode the company’s overall growth trajectory. Recent news highlights the 64th consecutive year of dividend increases, reinforcing J&J’s reputation as a dividend aristocrat, while ongoing talcum powder litigation poses a potential earnings risk; the company’s recent ASCO 2026 data on specialty drugs and the $85 million investment in CereVasc signal continued pipeline momentum and strategic diversification. Investors should watch for any revisions to the 2026 earnings guidance, updates on litigation settlements, progress of the CereVasc regulatory milestones, and any changes to the dividend payout ratio, as these factors will shape the company’s cash flow resilience and shareholder return outlook.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$2.85	-	-
Q1'26	$2.88	$2.70	-6.4%
Q4'25	$2.46	$2.46	-0.1%
Q3'25	$2.76	$2.80	+1.5%
Q2'25	$2.68	$2.77	+3.2%
Q1'25	$2.58	$2.77	+7.4%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$25.2B	-	-
Q1'26	$25.0B	$24.1B	-3.9%
Q4'25	$24.4B	$24.6B	+0.7%
Q3'25	-	$24.0B	-
Q2'25	-	$23.7B	-
Q1'25	-	$21.9B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

JNJ Stock Snapshot

JNJ is currently trading at $232.46, giving Johnson & Johnson a market cap of 560.33B and a P/E ratio of 26.6. Today's range spans $229.00–$235.22, with shares opening at $230.00 and moving down $0.34 (0.1%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 68/100.

Over the past year JNJ has traded between $149.04 and $251.71 - the current price is +56.0% off the 52-week low and -7.6% from the high.

Macro sensitivity and mega-cap scale make JNJ one of the most watched names in the Healthcare sector. The daily read is bullish: score 68/100, BUY signal, stock at $232.46 (in the upper portion of its 52-week range). Sentiment runs bullish at 68/100. The current P/E ratio stands at 26.6. With 560.33B in capitalization, this name gets bid up on good macro prints and defended on bad ones - the current technical alignment suggests the market is expressing a preference for the upside.

For portfolio managers constructing Healthcare exposure, a mega-cap with a BUY signal and bullish news backdrop represents the kind of conviction-generating setup that justifies moving from benchmark weight to overweight. The 68/100 technical score at $232.46 (in the upper portion of its 52-week range) provides the entry discipline; the 560.33B market cap provides the exit liquidity — a combination most position-sizing frameworks actively seek.

News Sentiment Analysis

Sentiment gathered from recent headlines

68/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Johnson & Johnson continues to deliver steady dividend growth, marking its 64th consecutive year of increases. Despite ongoing legal scrutiny over talcum powder claims, the company’s robust business model has weathered past crises, including the 1980s Tylenol incident. The dividend’s resilience underscores JNJ’s capacity to navigate regulatory and market pressures while maintaining shareholder returns. Investors should monitor the company’s litigation outcomes and any potential impact on earnings guidance.

What did this article say?

Johnson & Johnson’s stock advanced 2% on Friday, reaching a high of $235.22 before closing at $232.81. The rally was driven by analyst praise from Jim Cramer, who cited the company’s robust patent portfolio and high‑margin specialty drugs. Updates from ASCO 2026 highlighted encouraging data in autoimmunity, oncology, and myeloma, reinforcing expectations of long‑term revenue growth. The gains reflect renewed investor confidence in JNJ’s defensive positioning amid broader market volatility.

What did this article say?

J&J and Medtronic have jointly invested $85 million in CereVasc, a company focused on minimally invasive vascular devices. The capital infusion is intended to accelerate product development and bring new solutions to market faster. This move signals J&J’s continued commitment to expanding its vascular device portfolio and supporting innovative therapies. The partnership may also enhance CereVasc’s ability to secure regulatory approvals and commercialize its offerings more efficiently.

What did this article say?

Jim Cramer highlighted that Johnson & Johnson faces no major patent expirations, reinforcing the company’s long‑term revenue protection. The absence of looming patent cliffs supports a steady earnings trajectory and mitigates mid‑term growth risk. Investors should monitor any new product launches that could offset the lack of patent-driven revenue. The commentary suggests a neutral to slightly positive outlook, as patent stability is a core pillar of JNJ’s business model.

What did this article say?

An $850,000 equal‑weighted basket of KO, PEP, JNJ, CVX, and MO yields 4.2%, generating $36,000 per year. JNJ’s long‑standing dividend growth anchors the portfolio’s stability and tax efficiency, as qualified dividends are taxed at 15‑20% versus higher ordinary rates. The strategy highlights how dividend aristocrats can double retirement income in under a decade without relying on high‑risk income vehicles.

What did this article say?

Analysts question Johnson & Johnson’s ability to sustain growth amid mounting patent expirations, ongoing litigation, and regulatory scrutiny in China. The convergence of these headwinds could compress margins and delay new product introductions. While the company’s diversified portfolio offers some resilience, the risk profile has increased, prompting a more cautious stance. Traders should watch for updates on patent expirations, litigation settlements, and China regulatory developments.

What did this article say?

Johnson & Johnson’s dividend‑aristocrat status remains intact as the company raises 2026 EPS guidance to $11.45–$11.65, despite trading below consensus. The upward revision reflects confidence in the pharmaceutical and consumer health segments, offsetting a modest valuation discount. The firm’s long‑term payout history and stable cash flow continue to attract income‑focused investors. Market participants should monitor the company’s earnings releases and any changes to its dividend policy.

What did this article say?

Johnson & Johnson closed 2.21% higher at $228.17, outperforming the S&P 500’s 0.41% gain and the Nasdaq’s slight decline. Over the past month, the stock has slipped 0.61%, lagging the broader Medical sector’s 0.14% rise. Analysts anticipate the July 15 earnings report to deliver EPS of $2.83 and revenue of $25.04 billion, marking modest year‑over‑year growth. These figures will be critical for assessing the company’s near‑term valuation and guidance potential.

What did this article say?

At ASCO 2026, JNJ announced multiple practice‑changing clinical outcomes that expand its specialty drug footprint. Phase 3 PROTEUS data for apalutamide plus hormone therapy in high‑risk localized prostate cancer and TECVAYLI’s survival advantage in relapsed or refractory multiple myeloma were highlighted. Additionally, the company presented first‑in‑class FcRn‑blocker signals for systemic lupus erythematosus and promising results in Sjögren’s disease. These findings strengthen JNJ’s competitive edge in chronic disease therapeutics and may drive future revenue growth.

What did this article say?

JNJ was named among Newsweek’s 2026 Greenest Companies ranking, highlighting its progress in reducing emissions and enhancing climate resilience. The list evaluates 850 firms worldwide on environmental metrics such as emissions, deforestation, and temperature impacts. Inclusion may attract ESG‑focused investors and increase scrutiny from regulators. Traders should watch for any related sustainability disclosures and policy changes that could affect the company’s ESG profile.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

JNJ·Johnson & Johnson

EPS

Revenue

JNJ Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More